Efficacy and safety of Ezetimibe coadministered with Lovastatin in primary hypercholesterolemia

被引:166
作者
Kerzner, B
Corbelli, J
Sharp, S
Lipka, LJ
Melani, L
LeBeaut, A
Suresh, R
Mukhopadhyay, P
Veltri, EP
机构
[1] Schering Plough Res Inst, Kenilworth, NJ 07033 USA
[2] Hlth Trends Res, Baltimore, MD USA
[3] Buffalo Cardiol Pulm Associates, Williamsville, NY USA
[4] Clin Res Associates Inc, Nashville, TN USA
关键词
D O I
10.1016/S0002-9149(02)03236-8
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
This multicenter, randomized, double-blind, placebo-controlled clinical study assessed the efficacy and safety of ezetimibe administered with lovastatin in primary hypercholesterolemia. After dietary stabilization, a 2- to 12-week washout period, and a 4-week single-blind placebo lead-in period, 548 patients with low-density lipoprotein (LDL) cholesterol greater than or equal to 145 mg/dl (3.75 mmol/L) and less than or equal to250 mg/dl (6.47 mmol/L) and triglycerides less than or equal to350 mg/dl (3.99 mmol/L) were randomized to one of the following, administered daily for 12 weeks: ezetimibe 10 mg; lovastatin 10, 20, or 40 mg; ezetimibe 10 mg plus lovastatin 10, 20, or 40 mg; or placebo. The primary efficacy variable was percentage decrease in direct LDL cholesterol from baseline to end point for pooled ezetimibe plus lovastatin versus pooled lovastatin alone. Ezetimibe plus lovastatin significantly improved concentrations of LDL cholesterol, high-density lipoprotein (HDL) cholesterol, and triglycerides compared with lovastatin alone (p <0.01). The coadministration of ezetimibe provided an incremental 14% LDL cholesterol decrease, a 5% HDL cholesterol increase, and a 10% decrease in triglycerides compared with pooled lovastatin alone. Ezetimibe plus lovastatin provided mean LDL cholesterol decreases of 33% to 45%, median triglyceride decreases of 19% to 27%, and mean HDL cholesterol increases of 8% to.9%, depending on the statin dose. The coadministration of ezetimibe 10 mg plus the starting dose of lovastatin (10 mg) provided comparable efficacy to high-dose lovastatin (40 mg) across the lipid profile (LDL cholesterol, HDL cholesterol, and triglycerides). Ezetimibe plus lovastatin was well tolerated, with a safety profile similar to both lovastatin alone and placebo. The coadministration of ezetimibe and lovastatin may offer a view treatment option in lipid management of patients with hypercholesterolemia. (C) 2003 by Excerpta Medica, Inc.
引用
收藏
页码:418 / 424
页数:7
相关论文
共 14 条
  • [1] Ballantyne C, 2002, J AM COLL CARDIOL, V39, p227A
  • [2] Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III)
    Cleeman, JI
    Grundy, SM
    Becker, D
    Clark, LT
    Cooper, RS
    Denke, MA
    Howard, WJ
    Hunninghake, DB
    Illingworth, DR
    Luepker, RV
    McBride, P
    McKenney, JM
    Pasternak, RC
    Stone, NJ
    Van Horn, L
    Brewer, HB
    Ernst, ND
    Gordon, D
    Levy, D
    Rifkind, B
    Rossouw, JE
    Savage, P
    Haffner, SM
    Orloff, DG
    Proschan, MA
    Schwartz, JS
    Sempos, CT
    Shero, ST
    Murray, EZ
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 285 (19): : 2486 - 2497
  • [3] Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia
    Davidson, MH
    McGarry, T
    Bettis, R
    Melani, L
    Lipka, LJ
    LeBeaut, AP
    Suresh, R
    Sun, S
    Veltri, EP
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2002, 40 (12) : 2125 - 2134
  • [4] Efficacy and safety of a potent new selective cholesterol absorption inhibitor, Ezetimibe, in patients with primary hypercholesterolemia
    Dujovne, CA
    Ettinger, MP
    McNeer, JF
    Lipka, LJ
    LeBeaut, AP
    Suresh, R
    Yang, B
    Veltri, EP
    [J]. AMERICAN JOURNAL OF CARDIOLOGY, 2002, 90 (10) : 1092 - 1097
  • [5] FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499
  • [6] GRUNDY SM, 1993, JAMA-J AM MED ASSOC, V269, P3015, DOI 10.1001/jama.269.23.3015
  • [7] Harris W S, 1995, J Cardiovasc Risk, V2, P359, DOI 10.1097/00043798-199508000-00012
  • [8] Knopp R., 2001, ATHEROSCLEROSIS SUPP, V2, P90
  • [9] KNOPP RH, 2003, IN PRESS EUR HEART J
  • [10] Kosoglou T, 2001, J AM COLL CARDIOL, V37, p229A